Clinical Trial Search

Primary: 24 Hour Opioid Consumption — 51; 55; 27; 32 mg oral morphine equivalents (OMEs)

Primary: Subject-Reported Ocular Itching Score Assessed Over 110 to 210 Minutes in the Allergy Chamber — 0.94; 1.38 score on a scale

Primary: Change From Baseline in Plasma Arginine Concentration After 24 Weeks of Treatment — 0.244; 0.918 micromolar — p=<0.0001

Primary: Proportion of Biochemically Old Red Cell Units — 0.71; 0.86 proportion biologically old units — p=0.051

Primary: 90-day Utility Weighted Modified Rankin Scores (UW-mRS) — 5.2; 6.3; 6.8 score on a scale — p=0.002

Primary: Rate of Maternal HIV Viral Suppression — 128; 132 Participants

Primary: Percentage of Participants With Smoking Abstinence From Weeks 3 to Week 6 — 4.4; 25.3 percentage of participants — p=< 0.0001

Primary: Change From Baseline in Cohen-Manfield Agitation Inventory(CMAI) Score at 10 Weeks After Dosing. — -11.7; -15.2; -8.0 units on a scale — p=< 0.0001

Primary: Proportion of Patients Without Any Need for INV Until EoS — 98; 101; 12; 9 Participants

Primary: Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16 — 21.4; 47.7; 27.3; 33.3…

Primary: Lead-In Part: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03…

Primary: Feasibility of Phase III Trial — 20; 21; 10; 4 Participants

Primary: Change in Chronic Respiratory Disease Questionnaire (CRQ)- Dyspnea Score — 0.68; 0.71; 0.34; 0.83 score on a scale

Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants

Primary: Progression-free Survival (PFS) — 8.3; 5.4 Months — p=0.0040